Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:AARD NASDAQ:ACIU OTCMKTS:CHUC NASDAQ:CRGX On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAARDAardvark Therapeutics$8.30-2.2%$12.10$4.88▼$19.58$184.21MN/A68,683 shs50,043 shsACIUAC Immune$2.04-0.5%$2.13$1.43▼$3.98$205.84M1.65109,799 shs110,093 shsCHUCCharlie's$0.27+3.2%$0.13$0.03▼$0.28$67.73M0.95370,051 shs77,035 shsCRGXCARGO Therapeutics$4.47$4.45$3.00▼$25.45$216.17M0.31.73 million shsN/A7 Stocks to Buy And Hold ForeverEnter your email address and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAARDAardvark Therapeutics-2.24%-15.05%-34.59%-21.10%+829,999,900.00%ACIUAC Immune-0.49%-5.12%-6.42%+17.65%-35.03%CHUCCharlie's+3.18%+26.99%+172.01%+144.54%+142.09%CRGXCARGO Therapeutics0.00%0.00%0.00%+5.42%-73.66%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationAARDAardvark TherapeuticsN/AN/AN/AN/AN/AN/AN/AN/AACIUAC Immune2.0507 of 5 stars3.51.00.00.03.10.80.6CHUCCharlie's1.3351 of 5 stars0.05.00.00.01.91.70.6CRGXCARGO Therapeutics2.0504 of 5 stars2.90.00.00.02.01.71.3Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceAARDAardvark Therapeutics 3.00Buy$32.60292.77% UpsideACIUAC Immune 3.00Buy$12.00488.24% UpsideCHUCCharlie's 0.00N/AN/AN/ACRGXCARGO Therapeutics 1.86Reduce$15.40244.52% UpsideCurrent Analyst Ratings BreakdownLatest CHUC, CRGX, AARD, and ACIU Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails8/28/2025AARDAardvark TherapeuticsBank of AmericaSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$26.00 ➝ $25.008/14/2025AARDAardvark TherapeuticsRoyal Bank Of CanadaSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetOutperform ➝ Outperform$20.00 ➝ $19.007/8/2025CRGXCARGO TherapeuticsJefferies Financial GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetHold ➝ Hold$3.70 ➝ $5.006/30/2025AARDAardvark TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy$40.00(Data available from 8/29/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookAARDAardvark TherapeuticsN/AN/AN/AN/A$6.31 per shareN/AACIUAC Immune$31.02M6.60N/AN/A$0.90 per share2.27CHUCCharlie's$8.49M8.23N/AN/A$0.01 per share26.63CRGXCARGO TherapeuticsN/AN/AN/AN/A$4.91 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateAARDAardvark Therapeutics-$20.59MN/A0.00∞N/AN/AN/AN/AN/AACIUAC Immune-$57.83M-$0.58N/AN/AN/A-174.94%-49.35%-23.16%11/4/2025 (Estimated)CHUCCharlie's-$4.16M$0.0126.66∞N/A19.36%-174.49%36.91%11/17/2025 (Estimated)CRGXCARGO Therapeutics-$167.50M-$4.64N/AN/AN/AN/A-43.21%-37.26%11/11/2025 (Estimated)Latest CHUC, CRGX, AARD, and ACIU EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/21/2025Q2 2025CHUCCharlie'sN/A$0.02N/A$0.02N/A$2.54 million8/13/2025Q2 2025AARDAardvark Therapeutics-$0.52-$0.66-$0.14-$0.66N/AN/A8/5/2025Q2 2025ACIUAC Immune-$0.20-$0.25-$0.05-$0.25$1.98 million$1.65 million5/29/2025Q4 2024CHUCCharlie'sN/A-$0.01N/A-$0.01N/A$1.78 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthAARDAardvark TherapeuticsN/AN/AN/AN/AN/AACIUAC ImmuneN/AN/AN/AN/AN/ACHUCCharlie'sN/AN/AN/AN/AN/ACRGXCARGO TherapeuticsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioAARDAardvark TherapeuticsN/A14.0414.04ACIUAC ImmuneN/A1.331.33CHUCCharlie's0.071.610.61CRGXCARGO TherapeuticsN/A12.3712.37Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipAARDAardvark TherapeuticsN/AACIUAC Immune51.36%CHUCCharlie's7.80%CRGXCARGO Therapeutics93.16%Insider OwnershipCompanyInsider OwnershipAARDAardvark TherapeuticsN/AACIUAC Immune4.60%CHUCCharlie's20.90%CRGXCARGO Therapeutics2.92%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableAARDAardvark Therapeutics1821.70 millionN/AN/AACIUAC Immune140100.41 million95.79 millionOptionableCHUCCharlie's40262.43 million207.59 millionNot OptionableCRGXCARGO Therapeutics11648.36 million46.95 millionN/ACHUC, CRGX, AARD, and ACIU HeadlinesRecent News About These CompaniesCARGO Therapeutics, Inc. (NASDAQ:CRGX) Receives $15.40 Average Price Target from Analysts1 hour ago | americanbankingnews.comCARGO Therapeutics, Inc. (NASDAQ:CRGX) Receives $15.40 Consensus Price Target from Brokerages1 hour ago | americanbankingnews.comWall Street Zen Upgrades CARGO Therapeutics (NASDAQ:CRGX) to SellAugust 25, 2025 | marketbeat.comCARGO Therapeutics (NASDAQ:CRGX) Upgraded to Sell at Wall Street ZenAugust 23, 2025 | americanbankingnews.comCARGO Therapeutics Acquired by Concentra BiosciencesAugust 19, 2025 | tipranks.comCARGO Therapeutics (CRGX) Expected to Announce Earnings on MondayAugust 5, 2025 | marketbeat.comAlberta Investment Management Corp Takes $380,000 Position in CARGO Therapeutics, Inc. (NASDAQ:CRGX)August 5, 2025 | marketbeat.comTD Asset Management Inc Decreases Holdings in CARGO Therapeutics, Inc. (NASDAQ:CRGX)August 5, 2025 | marketbeat.comCARGO Therapeutics, Inc. (NASDAQ:CRGX) Given Average Rating of "Reduce" by BrokeragesAugust 3, 2025 | marketbeat.comMonaco Asset Management SAM Buys Shares of 139,028 CARGO Therapeutics, Inc. (NASDAQ:CRGX)July 31, 2025 | marketbeat.comJefferies Raises Price Target for Cargo Therapeutics (CRGX), Keeps Hold RatingJuly 29, 2025 | msn.comCARGO THERAPEUTICS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of CARGO Therapeutics, Inc. - CRGXJuly 25, 2025 | businesswire.comURGENT: The M&A Class Action Firm Launches Legal Inquiry for the Merger - CRGX, HSON, BRZH, and ENZBJuly 25, 2025 | prnewswire.comCRGX - Cargo Therapeutics Inc Financials | MorningstarJuly 19, 2025 | morningstar.comMCARGO THERAPEUTICS INVESTOR ALERT by the Former Attorney General of ...July 11, 2025 | morningstar.comMConcentra Biosciences Set to Acquire CAR T-Cell Innovator CARGO Therapeutics in Cash DealJuly 10, 2025 | hoodline.comHCARGO Therapeutics Enters into Agreement to Be Acquired by Concentra Biosciences for $4.379 in Cash per Share Plus a Contingent Value Right - Seeking AlphaJuly 9, 2025 | seekingalpha.comCARGO Therapeutics Enters into Agreement to Be Acquired by Concentra Biosciences for $4.379 in Cash per Share Plus a Contingent Value Right - MorningstarJuly 9, 2025 | morningstar.comMCARGO Therapeutics to be acquired by Concentra Biosciences in $4.379 a - Seeking AlphaJuly 9, 2025 | seekingalpha.com$HAREHOLDER ALERT: Class Action Attorney Juan Monteverde Investigates the Merger of CARGO Therapeutics, Inc. (NASDAQ: CRGX)July 9, 2025 | globenewswire.comSHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates CRGX and WNS on Behalf of ShareholdersJuly 9, 2025 | globenewswire.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeCHUC, CRGX, AARD, and ACIU Company DescriptionsAardvark Therapeutics NASDAQ:AARD$8.30 -0.19 (-2.24%) As of 08/29/2025 04:00 PM EasternAardvark Therapeutics, Inc. operates as a biotechnology company. It engages in the development of a novel small molecule therapeutics for obesity and metabolic diseases. The company was founded by Tien Lee in 2017 and is headquartered in San Diego, CA.AC Immune NASDAQ:ACIU$2.04 -0.01 (-0.49%) Closing price 08/29/2025 04:00 PM EasternExtended Trading$2.07 +0.03 (+1.47%) As of 08/29/2025 07:43 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.AC Immune SA, a clinical stage biopharmaceutical company, discovers, designs, and develops medicines and diagnostic products for the prevention and treatment of neurodegenerative diseases associated with protein misfolding. Its SupraAntigen and Morphomer platforms are designed to generate vaccines, antibodies, and small molecules, which selectively interact with misfolded proteins that are common in a range of neurodegenerative diseases. The company is developing Crenezumab, a humanized, conformation-specific monoclonal antibody, which is in Phase II clinical studies trial for the treatment of Alzheimer's disease (AD). It is also developing ACI-24, an anti-Abeta vaccine candidate that is in Phase II clinical study for AD, as well as completed Phase Ib clinical study for Down syndrome; ACI-35, an anti-Tau vaccine candidate that is in Phase Ib/2a clinical study; and Tau- positron emission tomography (PET) imaging tracer, which is in Phase II clinical study. In addition, the company is researching and developing small molecule Tau aggregation inhibitors for AD and NeuroOrphan indications. Further, it has discovery and preclinical stage molecules targeting range of neurodegenerative diseases, which include diagnostics targeting TDP-43, alpha-synuclein, and NLRP3. AC Immune SA has license agreements and collaborations with Genentech, Inc.; Biogen International GmbH; Janssen Pharmaceuticals, Inc.; Life Molecular Imaging SA; Eli Lilly and Company; and WuXi Biologics. The company was incorporated in 2003 and is headquartered in Lausanne, Switzerland.Charlie's OTCMKTS:CHUC$0.27 +0.01 (+3.18%) As of 08/29/2025 03:59 PM EasternCharlie's Holdings, Inc., together with its subsidiaries, formulates, markets, and distributes non-combustible nicotine-related, alternative alkaloid vapor, and hemp-derived vapor and edible products. It sells its products through distributors, specialty retailers, and third-party online resellers in the United States, the United Kingdom, Italy, Spain, New Zealand, Australia, and Canada. Charlie's Holdings, Inc. was founded in 2014 and is headquartered in Costa Mesa, California.CARGO Therapeutics NASDAQ:CRGX$4.47 0.00 (0.00%) As of 08/19/2025CARGO Therapeutics, Inc., a clinical-stage biotechnology company, develops chimeric antigen receptor (CAR) T-cell therapies for cancer patients. The company's lead program is CRG-022, an autologous CD22 CAR T-cell product candidate designed to address resistance mechanisms by targeting CD22, an alternate tumor antigen that is expressed in B-cell malignancies. It also develops CRG-023, a tri-specific CAR T product candidate that targets tumor cells with three B-cell antigen targets. The company was formerly known as Syncopation Life Sciences, Inc. and changed its name to CARGO Therapeutics, Inc. in September 2022. CARGO Therapeutics, Inc. was incorporated in 2019 and is headquartered in San Mateo, California. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Ollie’s Bargain Outlet: Buy it While It’s Still a Bargain Best Buy Marketplace: Potential Growth Catalyst or Risky Gimmick? CrowdStrike at a Crossroads: AI Halo vs. Risks Snowflake’s Snowballing Business and Robust Stock Price Outlook NVIDIA's Earnings Show a Green Light for Taiwan Semiconductor NVIDIA Stock Could Pull Back in September, But Don’t Bet on It 3 Reasons Gartner Could Be the Best Buy of Q3 NIO Just Got Its Second Upgrade of the Month, and It’s Big Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
